Our data support the notion that the combined inhibition of EGFR and COX-2 in colorectal cancer cells disturbs FOXM1/β-catenin axis impacting CSC subpopulation, and therefore might improve the efficacy of existing therapies in colorectal cancer. This evidence concerns the gene PTGS2 and colorectal cancer.